We develop treatment methods with unique properties in the therapeutic fields of migraine, pain related to cancer, opioid overdose and anaphylactic shock.
Download the Company Description.
Year end report, 2019
Annual General Meeting, 2020
Klaria Pharma AB - Interim Report Q3 2019
Klaria Pharma Holding Quarterly Report Q1 2019
We are using cookies to optimize your browsing experience. By continuing your browsing you consent to such use.